Read Techxen's PR post, especially the 2 paragraphs at the end on Dr. Reinhart and his role at the University of Jena where the CytoSorb registry is managed. Ask yourself: how could the WHA ignore the gains made in managing sepsis with blood filtration? The connection is clear. The WHA knows that tiny CTSO doesn't have the money, like a Bristol Myers, to promote its sepsis indication. CTSO operates on a shoe string. So this $4.6 million fund will, in part, tell docs about (CytoSorb) blood filtration. Don't think so? Read it closely again. This info wasn't included in this PR release for no reason.
“Worldwide, sepsis is one of the most common deadly diseases, and it is one of the few conditions to strike with equal ferocity in resource-poor areas and in the developed world,” said Dr. Konrad Reinhart, Chairman of the Global Sepsis Alliance. “In the developed world, sepsis is dramatically increasing by an annual rate of 5-13 per cent over the last decade, and now claims more lives than bowel and breast cancer combined. When sepsis is quickly recognized and treated, lives are saved but health care providers need better training because they are the critical link to preventing, recognizing, and treating sepsis.”
Dr. Konrad Reinhart is the Director of the Department of Anesthesiology and Intensive Care Medicine at the University of Jena, and the Chairman of the Global Sepsis Alliance and founding President of the German Sepsis Society, and the head of the SepNet sepsis trials network – a consortium of leading hospitals and intensivists throughout Germany who organized and ran government funded sepsis trials. University of Jena is where the multi-national registry for Cytosorb usage is being managed under the direction of the internationally renowned sepsis researcher Professor Dr. med. Frank Brunkhorst.
News 
Market Data 
Discover 
